Kennebec Savings Bank Has $61,000 Position in Becton, Dickinson and Company $BDX

Kennebec Savings Bank boosted its holdings in Becton, Dickinson and Company (NYSE:BDX) by 31.2% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 353 shares of the medical instruments supplier’s stock after buying an additional 84 shares during the period. Kennebec Savings Bank’s holdings in Becton, Dickinson and Company were worth $61,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of BDX. Saudi Central Bank acquired a new position in Becton, Dickinson and Company in the first quarter valued at approximately $26,000. Smallwood Wealth Investment Management LLC acquired a new position in Becton, Dickinson and Company in the first quarter valued at approximately $27,000. Alpine Bank Wealth Management acquired a new position in Becton, Dickinson and Company in the first quarter valued at approximately $29,000. Cornerstone Planning Group LLC lifted its holdings in Becton, Dickinson and Company by 341.4% in the first quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier’s stock valued at $29,000 after buying an additional 99 shares during the period. Finally, Kelly Lawrence W & Associates Inc. CA acquired a new stake in Becton, Dickinson and Company in the first quarter worth $31,000. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, EVP Michael David Garrison sold 1,185 shares of the firm’s stock in a transaction on Friday, July 18th. The shares were sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the transaction, the executive vice president owned 4,887 shares of the company’s stock, valued at approximately $881,077.23. This trade represents a 19.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Claire Fraser sold 917 shares of Becton, Dickinson and Company stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total transaction of $171,937.50. Following the completion of the transaction, the director directly owned 22,226 shares of the company’s stock, valued at approximately $4,167,375. This trade represents a 3.96% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 3,023 shares of company stock valued at $562,036. 0.36% of the stock is owned by insiders.

Analysts Set New Price Targets

BDX has been the topic of several analyst reports. Wall Street Zen upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Wells Fargo & Company increased their target price on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an “equal weight” rating in a report on Friday, August 8th. Royal Bank Of Canada initiated coverage on shares of Becton, Dickinson and Company in a report on Thursday, September 25th. They issued a “sector perform” rating and a $211.00 target price on the stock. Morgan Stanley increased their target price on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a report on Monday, August 11th. Finally, Argus increased their target price on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a report on Monday, September 15th. Three analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $205.40.

Becton, Dickinson and Company Stock Up 2.0%

Becton, Dickinson and Company stock opened at $190.90 on Thursday. The company has a market cap of $54.72 billion, a P/E ratio of 34.33, a price-to-earnings-growth ratio of 1.51 and a beta of 0.25. Becton, Dickinson and Company has a 1-year low of $163.33 and a 1-year high of $251.99. The company has a fifty day simple moving average of $188.71 and a 200 day simple moving average of $188.20. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, beating analysts’ consensus estimates of $3.40 by $0.28. The business had revenue of $5.51 billion during the quarter, compared to the consensus estimate of $5.50 billion. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The firm’s revenue for the quarter was up 10.4% compared to the same quarter last year. During the same quarter last year, the firm earned $3.50 earnings per share. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. Research analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 30th. Investors of record on Monday, September 8th were given a $1.04 dividend. The ex-dividend date of this dividend was Monday, September 8th. This represents a $4.16 dividend on an annualized basis and a yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 74.82%.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.